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Abstract
Purpose The quality of patient-reported outcome (PRO) data can be compromised by non-response (NR) to scheduled 
questionnaires, particularly if reasons for NR are related to health problems, which may lead to unintended bias. The aim 
was to investigate whether electronic reminders and real-time monitoring improve PRO completion rate.
Methods The population-based study “Quality of life in Danish multiple myeloma patients” is a longitudinal, multicentre 
study with consecutive inclusion of treatment-demanding newly diagnosed or relapsed patients with multiple myeloma. 
Education of study nurses in the avoidance of NR, electronic reminders, 7-day response windows and real-time monitoring 
of NR were integrated in the study. Patients complete PRO assessments at study entry and at 12 follow-up time points using 
electronic or paper questionnaires. The effect of the electronic reminders and real-time monitoring were investigated by 
comparison of proportions of completed questionnaires before and after each intervention.
Results The first 271 included patients were analysed; of those, 249 (85%) chose electronic questionnaires. Eighty-four 
percent of the 1441 scheduled PRO assessments were completed within the 7-day response window and 11% after real-time 
monitoring, achieving a final PRO completion rate of 95%. A significant higher proportion of uncompleted questionnaires 
were completed after the patients had received the electronic reminder and after real-time monitoring.
Conclusions Electronic reminders and real-time monitoring contributed to a very high completion rate in the study. To 
increase the quality of PRO data, we propose integrating these strategies in PRO studies, however highlighting that an 
increase in staff resources is required for implementation.
Keywords Missing data · Health-related quality of life · Patient-reported outcomes · Patient-reported outcomes completion 
rate · Multiple myeloma
Introduction
Multiple myeloma (MM) is an incurable malignancy of 
plasma cells in the bone marrow. MM is associated with 
severe morbidity, specifically caused by bone destruction 
and pathological bone fractures, renal dysfunction, high 
infection rate and potential physical disability [1, 2]. The 
prognosis of MM has improved markedly over the past 
20 years, and the median survival of MM patients under 
the age of 70 has increased from 3 years [3] to 6–7 years 
[4, 5]. The improved prognosis is mediated by the introduc-
tion of high dose chemotherapy with autologous stem cell 
support (HDT) in the 1990s, new treatment options with 
immunomodulatory drugs (IMiDs), such as thalidomide, 
lenalidomide and pomalidomide [6–8], and the proteasome 
inhibitors, bortezomib, carfilzomib and ixazomib [9–11]. 
Most recently, the monoclonal antibodies elotuzumab and 
daratumumab [12, 13] have been introduced, and therefore 
the prognosis is expected to improve even further in coming 
years [14].
Treatment choice in MM depends on the patients’ age, 
disease complications, existing comorbidity and whether 
the patient is judged fit for specific regimens, such as HDT. 
Treatment usually involves repeated cycles of a 2–3 drug 
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combination therapy with a proteasome inhibitor, IMiD, 
cytostatic agent and/or steroid. Treatment implies a risk of 
both acute adverse events, such as infections, as well as late 
effects, such as peripheral neuropathy and fatigue [15–18].
Patients with MM report a high symptom burden. Com-
mon symptoms include fatigue, pain, constipation, insomnia 
and tingling in the hands/feet, with a consequent decrease 
in physical and cognitive functioning [19–21]. Compared to 
patients with other haematological malignancies, patients 
with MM report low health-related quality of life (HRQoL) 
[21, 22]. Longitudinal HRQoL studies of patients with MM 
suggest that clinically beneficial improvements in HRQoL 
are more likely during primary treatments than during treat-
ment for relapse [23].
The patients’ experience of symptoms and HRQoL can 
be validly and reliably captured with patient-reported out-
come (PRO) questionnaires [24]. Integration of PROs into 
routine care management of patients with advanced cancer 
is associated with increased overall survival and reduction 
of the symptom burden [25, 26]. Typically, PRO assessments 
are scheduled at key time points and when a questionnaire 
is not completed at a scheduled time, it is referred to as a 
non-response (NR). Consequently, missing data can lead to a 
variety of problems, more so as NR rates increase, including 
loss of study power and precision [27, 28]. Further, there is 
risk of bias if the reason for NR is related to the patient’s 
health status and appropriate analysis methods are not 
applied. For example, if only complete case analysis meth-
ods are used, there is a risk of overestimated HRQoL and 
underestimated toxicity [27–29]. This is due to the analysis 
being based on available data from patients with completed 
PRO assessments and who presumably have better HRQoL, 
while patients who drop out might have more toxicity and 
a worse HRQoL [27, 30–34]. Thus, NR represents a threat 
to internal and external validity and is one of the inherent 
barriers in establishing high quality PRO data for use in 
patient-centred care [35–37]. Several strategies designed to 
minimize NR have been proposed, and these can be inte-
grated into the study design, protocol and implementation 
procedures for the PRO study [29]. These include ensuring 
that staff are aware of the importance of reducing NR and 
have access to written study procedure guidelines and sup-
port [29, 31]. Also, given the time-sensitive nature of PRO 
data, real-time monitoring of PRO completion rates during 
the study is recommended [38]. However, we are not aware 
of any studies that have assessed and documented the effec-
tiveness of such strategies in reducing NR.
The study “Quality of life in Danish multiple myeloma 
patients” (QoL-MM) is a national multicentre, prospec-
tive, observational and primarily web-based survey with 
real-time monitoring of NRs. Several strategies to reduce 
NR have been implemented including education of study 
nurses, electronic reminders and real-time monitoring of 
PRO completion. The aim of this analysis was to investigate 
whether electronic reminders and real-time monitoring of 
NRs improve PRO completion rate.
Methods
The QoL-MM study includes newly diagnosed or relapsed, 
treatment-demanding patients with MM who, according 
to International Myeloma Working Group (IMWG) crite-
ria, are eligible for inclusion [2]. Broad inclusion criteria 
ensure inclusion of a population-based, representative cohort 
of MM patients. Only, patients who are not able to under-
stand the Danish language or who are diagnosed with a psy-
chiatric condition are ineligible. Study sites include all 10 
Danish departments of haematology. The goal is to recruit 
800 patients, and each patient is followed for 24 months or 
until early drop-out due to withdrawal of consent, death or 
permanent lack of ability to fill out the questionnaires. The 
patients are introduced to the study by their treating phy-
sician or nurse, and written informed consent is obtained 
prior to inclusion. Demographic data are collected as part 
of the inclusion interview by a local study nurse. Moreover, 
the patients provide information related to activity of daily 
living (ADL), instrumental ADL and self-reported diseases, 
summarized into the Charlson Comorbidity Index [39–41]. 
This information is used to calculate the Freiburger Comor-
bidity Index of 0-3 and the IMWG myeloma frailty score 
which divides the patients into three categories of “Frail”, 
“Intermediate Fitness” or “Fit” [42, 43]. The patient’s Kar-
nofsky Performance status was assessed by the local study 
nurse [44]. Clinical data, e.g. date of diagnosis, MM subtype 
and the prognostic score, International Staging System, are 
collected from The Danish Multiple Myeloma Registry [45, 
46]. Data on admissions, discharges and other hospital pro-
cedures are captured from The National Registry of Patients 
[47].
PRO study design
Patients complete questionnaires at study entry and at 12 
follow-up time points during a 24 month period. The patient 
left the study before 24 months in case of death, withdrawn 
consent or entering a state with permanently inability to 
complete a questionnaire. The follow-up target dates for 
completion of questionnaires are every 4 weeks for the first 
6 months and thereafter every 3 months until 24 months. 
Depending on the PRO assessment time point, the patient 
completes between two and four PRO instruments, equiva-
lent to 50–85 items. Each set of questionnaires is sequenced 
to begin with the cancer specific instrument European 
Organisation for Research and Treatment of Cancer Qual-
ity of life QLQ-C30 (EORTC QLQ-C30) [24] followed 
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by the Multiple Myeloma module QLQ-MY20 (EORTC 
QLQ-MY20) [48], the Chemotherapy-Induced Peripheral 
Neuropathy module (EORTC QLQ-CIPN20) [49] and the 
Short-form health survey version 2 (SF12v2) [50].
PRO data collection procedures
Participants are asked to complete the entire set of ques-
tionnaires at one time, preferably on the target date and 
no later than 7 days hereafter, which is the 7-day response 
window for all follow-up questionnaires. The patients are 
furthermore encouraged to use the web-based questionnaire 
method, where a link is sent to the patients’ email on the tar-
get date. However, patients can choose the paper-and-pencil 
method, if preferred. A REDCap database automatically 
sends the emails on the target date and email reminders [51].
At baseline, the patient may complete the questionnaires 
alone or with assistance from the study nurse using a tablet 
or paper. The baseline questionnaires can also be completed 
at home by computer or tablet; however the study nurse must 
ensure that the questionnaires have been completed no later 
than on the day of anti-myeloma treatment. The patient is 
excluded as a screening failure if there is an uncompleted 
baseline questionnaire or missed completion of one or more 
of the four baseline PRO instruments by 3 days after start of 
anti-myeloma treatment.
Patients who choose to use paper questionnaires receive 
three sets of questionnaires at the inclusion interview to 
complete at four, eight and 12 weeks follow-up. The target 
date of each set of questionnaires is written on the cover 
page with the contact information of the local study nurse. 
The patients are asked to bring the completed question-
naires to the outpatient clinic at a scheduled appointment. 
To remind the patient to complete the first follow-up paper 
questionnaire, the local study nurse contacts the patient 
at 4 weeks. After week 12, it is the responsibility of the 
local study nurses to provide the next three sets of question-
naires to the patient for completion at 16 and 20 weeks and 
6 months. In this way, the local study nurse provides paper 
questionnaires to the patients who chose to complete the 
follow-up questionnaires in paper, three times during the 
24 months. Completed paper questionnaires are uploaded to 
the REDCap database by the local study nurse and centrally 
entered continuously during the study period by the staff at 
the study office.
Strategies to minimize intermittent non‑responses
All local study nurses are informed about the importance 
of minimizing missing items and NR to a questionnaire or 
set of questionnaires and are trained in appropriate pro-
cedures to minimize missing data. Local study nurses are 
permitted to provide support to frail patients or patients 
who temporarily lack the ability to independently complete 
questionnaires. In such cases, the local study nurse reads the 
items and response categories aloud and marks the patient’s 
answers on his or her behalf. The aim is for this to be done 
within the 7-day response window after the target date. If 
the patient does not have an appointment in the outpatient 
clinic within this time frame, but has a scheduled appoint-
ment a few days before the target date, the study nurse pro-
vides the patient with the questionnaire at that appointment. 
Otherwise, the questionnaire is completed after the 7-day 
response window.
For patients using the web-based completion method who 
have not completed the electronic questionnaire at day 4, 
a reminder is automatically sent to the patients email. If a 
patient has still not answered the questionnaire on day 7 
after the target date, the local study nurse is notified by the 
central study office during week days, as part of real-time 
monitoring of NR. In this situation, the local study nurse 
has 2 week days to contact the patient, ascertain and docu-
ment the reason for NR and to invite the patient to complete 
the questionnaire. The study nurses have access to a writ-
ten guideline of all project related tasks, and in case there 
is need for further clarification of a project procedure, the 
study office can be contacted by telephone or email during 
week days.
Real-time monitoring of PRO completion or NR for both 
web-based and paper-based PRO questionnaire completion 
is carried out by the study office. If a patient has completed 
some or all items of the EORTC QLQ-C30, which is the 
first questionnaire at every scheduled PRO assessment 
time point, the follow-up PRO assessment is defined as 
completed. Missing items and partly completed question-
naires or sets of questionnaires are not part of the real-time 
monitoring.
The participating departments are financially compen-
sated for managing a NR, providing guidance to a patient to 
complete a questionnaire and when three completed paper 
questionnaires are either provided or collected.
Information to the participants
As part of the inclusion interview, all patients are informed 
about the importance of completing the follow-up question-
naires within the 7-day response window, and that the study 
nurse will contact them if they have not completed a ques-
tionnaire by the seventh day. A part of the information pro-
vided to the patients choosing the electronic platform is that 
they will receive an email reminder, if they have not com-
pleted a scheduled questionnaire within 4 days. The patients 
are informed about the reason why they will be contacted in 
case of an NR within the 7-day response window, including 
that this could be due to a decline in the patients’ HRQoL. 
Patients are informed that participation and completing 
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questionnaires in the study are voluntary and that choosing 
to skip a scheduled questionnaire will not have any conse-
quences for the patient. All patients receive the study nurses’ 
contact information and are encouraged to seek support in 
case of questions, technical challenges or deciding to change 
the method of completion.
Patient cohort and data analysis
The patient cohort for this paper include all patients who 
consented to QoL-MM by 16th August 2018 and who 
reached at least the first follow-up PRO assessment time 
point at week 4. Questionnaires which are completed before 
or within the 7-day response window are defined as “on-time 
responses”. In case the patient complete the questionnaire at 
day 7 after the target date or later, the response is defined as 
“salvage response”, and the remainder were categorized as a 
“never response”. The PRO completion rate was calculated 
as the number of completed on-time and salvage responses 
as a proportion of the number of scheduled PRO assessments 
expected to be completed [52]. Also, we calculated the rate 
of on-time and salvage responses. The effect of electronic 
reminders was estimated by comparing the number of com-
pleted questionnaires completed by patients who had chosen 
to complete the follow-up questionnaires electronically at 
day four compared to day three in relation to the number of 
questionnaires still not completed. The same was carried 
out to estimate the effect of real-time monitoring, where the 
number of electronic completed questionnaires at day 6 and 
day 7 was compared. Chi square test was used as statisti-
cal analysis method for the effect analyses. We investigated 
seven baseline patient characteristics as predictors for on-
time response and questionnaire completion (age, gender, 
Karnofsky Performance Status Scale, IMWG frailty score, 
CCI, relapsed disease and completion of the questionnaires 
by paper). The analyses were performed by mixed effects 
logistic regression with a random effect to take account non-
independence of observations from the same patient. P-val-
ues < 0.05 were considered statistically significant. Data are 
presented by descriptive analyses using Stata version 15.
Results
As of August 16th 2018, 481 patients were found eligible for 
the QoL-MM study, and hereof 292 provided written con-
sent for participation and inclusion in the study. Of the 292 
patients included, 271 had reached at least the first follow-up 
PRO assessment time point at 4 weeks and were included 
in the analyses. Patient and disease characteristics are pre-
sented in Table 1. Of all patients, 55% had newly diagnosed 
symptomatic MM of which 52% started an induction regi-
men with planned HDT at study entry. A daratumumab 
containing regimen was the most frequently used regimen 
in treatment of relapse MM and 24% of the patients with 
relapse started fifth or later line of therapy. Twenty-four per-
cent of both newly diagnosed and relapse MM were 76 years 
or older, and 17% of the NDMM patients and 12% of the 
RMM were characterized as “Frail” according to the IMWG 
myeloma frailty score.
Electronic completion of follow-up questionnaires was 
chosen by 85% of the 271 patients, and 15% chose the 
paper-and-pencil method. Three patients changed mode of 
answering during follow-up, two from electronic method to 
paper method, as the electronic method was found to be too 
complicated.
PRO completion rate
Per protocol, for the study cohort (n = 271), 1441 scheduled 
follow-up questionnaires were expected to be completed at 
the time of analysis. The number of patients and completed 
questionnaires (on-time and salvage) and never-responses at 
each follow-up time point are presented in Fig. 1. The rea-
sons for reduction in number of patients in the flow diagram 
are due to early drop-out or end of follow-up. The largest 
proportion of never-responses with the first year of follow-up 
was at 4 weeks 7% (19 questionnaires out of 271 expected).
Of the 1441 scheduled questionnaires, 1214 (84%) were 
completed on-time. Of the 227 questionnaires that were not 
completed on-time, 153 (67%) were salvaged responses 
and 74 (33%) were never completed. When adding the sal-
vage responses to the on-time responses, a total 1367 of the 
scheduled questionnaires were completed, equivalent to a 
PRO completion rate of 95%.
Pattern of response and effect of electronic 
reminder and real‑time monitoring
Questionnaire completion patterns are presented in Fig. 2; 
Table 2. Of the 1367 scheduled questionnaires, 553 (40%) 
were answered on the target date, 417 (31%) were com-
pleted on days one to three. For estimation of the effect of 
the reminder, at day 4, 100 out of 392 not completed elec-
tronic questionnaires were completed, which is 25.5% (95% 
CI 21.3%; 30.1%). At day 3, 75 out of 467 not completed 
questionnaires were completed, which is 16.1% (95% CI 
12.8; 19.7). A significantly higher proportion of uncom-
pleted questionnaires were completed after the patients had 
received the electronic reminder (p < 0.001). For estimation 
of the effect of real-time monitoring, at day 7, 58 out of 
189 not completed questionnaires were completed (30.7%, 
95% CI 24.2%; 37.8%). This is a significantly higher pro-
portion (p < 0.001) than at day 6, where 35 out of 223 not 
completed questionnaires were completed (15.7%, 95% CI 
11.2%; 21.1%).
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Predictors for non‑completion
The strongest predictors for non-completion of scheduled 
questionnaires were IMWG frailty score (Intermediate fit-
ness; p-value 0.009, Frail; p-value 0.001) and choosing 
paper questionnaires (p-value 0.005). A weak association 
for non-completion was found for CCI 1 (p-value 0.042) 
and a weak association for completion was found for male 
gender (p-value 0.044). When we made the analysis for 
on-time completion only, the association between paper 
completion method and non-completion was persis-
tent (p-value 0.047) and Karnofsky Performance Status 
Scale ≤ 70% (p-value 0.025) appeared as a predictor for 
non-completion, too. The results of the mixed effects 
logistic regression analysis are presented in Table 3. We 
repeated the analysis but adjusted for time point and found 
similar results (data not shown).
Table 1  Demographic and disease characteristics at entry
P number of patients, SD standard deviation, IQR interquartile range, IMWG International Myeloma Working Group, HDT high dose therapy 
with stem cell support, ISS International Staging System
a Separated, divorced, widow or unmarried
b Missings are due to time delay in entering disease data into The Danish National Multiple Myeloma Registry or unknown
c Glucocorticosteroid treatment is not registered in The National Registry of Patients
Characteristics Newly diagnosed patients with MM P = 165 Relapse patients with MM P = 127
Mean age (SD) 67.0 (9.7) 68.7 (9.5)
Median age, years (IQR) 68 (60; 74) 70 (63; 74)
 Age ≤ 65/66–75/≥ 76 years, N (%) 56 (34%)/69 (52%)/40 (24%) 40 (32%)/57 (45%)/30 (24%)
Sex, female/male, N (%) 70 (42%)/95 (58%) 42 (33%)/85 (67%)
Marital status, married or cohabiting/singlea, N (%) 131 (79%)/34 (21%) 99 (78%)/28 (22%)
Weekly alcohol intake, no alcohol intake/1–7/> 8 
items, N (%)
42 (25%)/81 (49%) 42 (25%) 24 (19%)/70 (55%)/33 (26%)
Daily smoking, yes/former smoker/never smoker, 
N (%)
19 (12%)/75 (45%) 71 (43%) 15 (12%)/57 (45%)/55 (43%)
Charlson Comorbidity Index, 0/1/2/≥ 3, N (%) 100 (61%)/20 (12%)/27 (16%) 18 (11%) 66 (52%)/28 (22%)/21 (17%)/12 (9%)
Freiburg Comorbidity Index, 0/1/2 or 3, N (%) 124 (75%)/40 (24%)/1 (1%) 109 (86%)/17 (13%)/1 (1%)
IMWG Myeloma Frailty Score, Fit/intermediate 
fitness/Frail, N (%)
82 (50%)/55 (33%)/28 (17%) 77 (61%)/35 (28%)/15 (12%)
Karnofsky Performance Status Scale, 
100/90/80/≤ 70%, N (%)
55 (33%)/54 (33%)/30 (18%)/26 (16%) 28 (22%)/65 (51%)/23 (18%)/11 (9%)
Mean time from diagnosis to inclusion (years) (SD) 0.16 (0.77) 4.69 (3.05)
M-component subtype, IgG/IgA/light 
chain/> 1 M-component/non-secretory/missingb
28 (63%)/11 (25%)/3 (7%)/0/2 (5%)/121 59 (63%)/21 (22%)/8 (9%)/2 (2%)/4 (4%)/33
International Staging System, ISS I/ISS II/ISS III/
missingb, N (%)
13 (30%)/19 (44%)/11 (26%)/122 11 (19%)/34 (59%)/13 (22%)/69
Number of lines of therapy
 First line 165 (100%) –
 Second line – 50 (39%)
 3–4 line – 47 (37%)
 5 or more lines – 30 (24%)
Anti-myeloma  treatmentc
 Induction therapy and HDT 86 (52%) 8 (6%)
 Melphalan-prednisolon-bortezomib 47 (28%) 3 (2%)
 Containing daratumumab 0 70 (55%)
 Containing elotuzumab 0 7 (6%)
 Lenalidomide 6 (4%) 8 (6%)
 Containing Ixazomib 1 (1%) 7 (6%)
 Containing carfilzomib 0 15 (12%)
 Containing pomalidomide 1 (1%) 6 (5%)
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Fig. 1  Flow diagram of the 
patients in follow-up. The 
reduction of patients in follow-
up was due to drop-out or end 
of follow-up
Baseline 
271 parcipang paents 
271 completed quesonnaires, 0 never responses 
4 weeks 
271 parcipang paents 
252 completed quesonnaires, 19 never responses 
8 weeks 
245 parcipang paents 
234 completed quesonnaires, 11 never responses 
12 weeks 
215 parcipang paents 
207 completed quesonnaires, 8 never responses 
16 weeks 
197 parcipang paents 
191 completed quesonnaires, 6 never responses 
20 weeks 
187 parcipang paents 
175 completed quesonnaires, 12 never responses 
6 months 
165 parcipang paents 
156 completed quesonnaires, 9 never responses 
9 months 
108 parcipang paents 
101 completed quesonnaires, 7 never responses 
12 months 
43 parcipang paents 
41 completed quesonnaires, 2 never responses 
15 months 
17 parcipang paents 
17 completed quesonnaires, 0 never responses 
18 months 
8 parcipang paents 
8 completed quesonnaires, 0 never responses 
21 months 
2 parcipang paents 
2 completed quesonnaires, 0 never responses 
24 months 
0 parcipang paents 
0 completed quesonnaires, 0 never responses 
Drop-out, p=12 
End of follow-up, p=14 
Drop-out, p=4 
End of follow-up, p=26 
Drop-out, p=9
End of follow-up, p=9 
Drop-out, p=1
End of follow-up, p=9 
Drop-out, p=3
End of follow-up, p=19 
Drop-out, p=5
End of follow-up, p=52 
Drop-out, p=8 
End of follow-up, p=57 
Drop-out, p=1
End of follow-up, p=25 
Drop-out, p=0 
End of follow-up, p=9 
Drop-out, p=0 
End of follow-up, p=6 
Drop-out, p=0 
End of follow-up, p=0 
Drop-out, p=0 
End of follow-up, p=0 
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Discussion
The aim of the analysis was to investigate whether the strat-
egies used to minimize NRs to scheduled questionnaires 
could increase PRO completion rate in a longitudinal study 
of MM patients receiving anti-myeloma treatment. Our 
initiatives included education of study nurses, electronic 
reminders and real-time monitoring of NR. A significant 
higher proportion of uncompleted questionnaires were com-
pleted after the patients had received the electronic reminder 
and after real-time monitoring. Those strategies resulted 
in a very high PRO completion rate of 95%, with just 5% 
non-response.
PRO completion rates in longitudinal studies of patients 
with MM are often not reported, and of the studies, where 
this information was reported, the PRO completion rate 
was 78–98% [53]. Only one study has reported a higher 
PRO completion rate compared to our findings. This was 
the NMSG 4/90 study by Gulbrandsen et al. [54], where 
the PRO completion rate of the historical control group of 
newly diagnosed patients with MM was 98%. This historical 
control group originates from the EORTC QLQ-C30 vali-
dation study of patients with MM [55]. One of the aims in 
the validation study was to evaluate the applicability of the 
questionnaire in a cohort of patients with MM and included 
sampling of data concerning the patient’s need for assistance 
in completing the questionnaires. The authors found that up 
to 30% of the MM patients reported need of assistance in 
completing the questionnaire. Other strategies of how this 
high PRO completion rate was achieved are not described 
in the paper [55].
When the QoL-MM study was designed, there had been 
particular focus on how we could minimize NR. We intro-
duced real-time monitoring of NR and provided the patients 
with reminders. Staff resources were dedicated for this pur-
pose, software as well as a high proportion of the patients 
choosing the web-based questionnaire method made it pos-
sible, and we succeeded in reaching a high PRO completion 
rate. Still, some NR could not be avoided. We found that low 
performance status at the time of inclusion and choosing 
paper-and-pencil method were predictors for not complet-
ing the questionnaires on-time. Risk of never response was 
higher for females, un-fit patients at baseline and choosing 
paper method for questionnaire completion. Special atten-
tion and guidance should be provided from the study staff to 
Fig. 2  Day of response to paper and electronic questionnaires. Day 0 
is the target day, when the patients were instructed to complete the 
questionnaires. The patients completing the questionnaires electron-
ically received an email with a link to the questions on day 0. The 
local nurses provided the paper questionnaires with inscribed target 
dates for patients completing on paper to answer the questionnaires at 
home. If the patient had completed the EORTC QLQ-C30, which was 
the first health-related quality of life instrument in each set of ques-
tionnaires, the set of questionnaires was defined as completed
Table 2  Pattern of response
Questionnaires completed before or within the 7-day response win-
dow are termed “on-time responses”. Questionnaires completed after 
the 7-day response window are termed “salvage responses”. Five per-
cent of the scheduled questionnaires were never completed
*If the patients completing questionnaires electronically did not 
respond by day 4, a reminder was sent by email
Proportion of 
scheduled question-
naires
Time of response Completed follow-
up questionnaires 
(Q = 1367)
On-time response Before day 0 37 (3%)
84%  Electronic 0
 Paper 37
Day 0—the target day 553 (40%)
 Electronic 481
 Paper 72
Day 1–3 417 (31%)
 Day 1 212
 Day 2 128
 Day 3 77
 Electronic 403
 Paper 14
Day 4*–6 207 (15%)
 Day 4 101
 Day 5 70
 Day 6 36
 Electronic 203
 Paper 4
Salvage response Day 7 or later 153 (11%)
11%  Day 7 60
 Day 8 32
 Day 9 13
 After day 9 48
 Electronic 134
 Paper 19
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avoid NR from those patients. Information about the clini-
cal status of patients when they fail to complete a sched-
uled questionnaire and the reason for NR might assist the 
PRO researchers in making the correct assumption for the 
underlying missing data mechanisms [27, 28, 56]. The link 
between the documented reasons, the predictors for NR and 
the missing data mechanisms as well as estimation of the 
impact of NR and patient drop-out on HRQoL results will 
be investigated in future analyses of the QoL-MM study.
The overall aim of the QoL-MM study is to describe the 
quality of life of the general population of patients with MM 
from diagnosis to late, advanced disease throughout differ-
ent kinds of anti-myeloma therapies [57]. Methodological 
considerations concerning PRO assessment time points were 
included as part of the study planning. Clinical visits are 
frequently chosen time points for PRO assessment in clinical 
trials of MM patients [53]. This decision has the advantage 
of reducing the risk of NR, since patients have the oppor-
tunity to complete the questionnaires at the hospital with 
assistance from the study nurse. Disadvantages in using day 
1 of treatment cycles include a potential risk of underesti-
mation of toxicities that occur after day 1 and not captur-
ing periods with temporary decline in HRQoL, resulting in 
rescheduling of chemotherapy [58]. We chose to collect the 
PRO data in QoL-MM at predefined calendar time points to 
meet the overall study aim and thereby capture HRQoL at 
regular non-clinic time points throughout the MM patients´ 
diverse disease trajectories. This decision could have made 
the study vulnerable for low PRO completion rates, since 
the general population of patient with MM can be frail and 
are at risk of adverse events, hospital admissions, as well as 
risk of physical and mental disabilities caused by the disease 
and therapy. Therefore, we implemented the educational and 
procedural strategies to reduce NRs. The same strategies 
might be useful to ensure high PRO completion rate in rou-
tine assessment and clinical utilization of PRO measures in 
the broad group of cancer patients [59].
Table 3  Results of mixed 
effects logistic regression 
analysis
Bold odd ratio and P-values represent statistically significant associations
OR odd ratio, IMWG International Myeloma Working Group
Predictor Completed at all Completed on-time
OR (95% CI) P-value OR (95% CI) P-value
Age group
 < 65 1 (Reference) 1 (Reference)
 65–74 1.45 (0.41, 5.10) 0.560 1.11 (0.63, 1.95) 0.727
 75+ 4.27 (0.74, 24.56) 0.103 1.77 (0.75, 4.17) 0.191
Gender
 Female 1 (Reference) 1 (Reference)
 Male 3.00 (1.03, 8.73) 0.044 0.88 (0.53, 1.46) 0.611
Karnofsky Performance Status
 100% 1 (Reference) 1 (Reference)
 90% 0.77 (0.22, 2.75) 0.689 0.73 (0.39, 1.36) 0.315
 80% 1.76 (0.35, 8.70) 0.490 0.49 (0.24, 1.00) 0.050
 ≤ 70% 1.54 (0.20, 11.87) 0.679 0.35 (0.14, 0.88) 0.025
IMWG Fraility Score
 Fit 1 (Reference) 1 (Reference)
 Intermediate Fitness 0.11 (0.02, 0.57) 0.009 0.53 (0.24, 1.19) 0.126
 Frail 0.02 (0.002, 0.21) 0.001 0.40 (0.13, 1.19) 0.100
Charlson Comorbidity Index
 0 1 (Reference) 1 (Reference)
 1 0.23 (0.06, 0.95) 0.042 0.92 (0.46, 1.84) 0.806
 2 2.31 (0.43, 12.55) 0.332 1.19 (0.49, 2.90) 0.703
 3+ 2.95 (0.42, 20.48) 0.274 1.77 (0.65, 4.81) 0.263
Relapsed disease
 No relapse 1 (Reference) 1 (Reference)
 Relapse 0.82 (0.28, 2.41) 0.712 0.76 (0.46, 1.25) 0.277
Questionnaire method
 Electronic 1 (Reference) 1 (Reference)
 Paper 0.15 (0.04, 0.57) 0.005 0.48 (0.23, 0.99) 0.047
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Another strategie we chose was to use a pre-planned 
time frame of 7 days for each scheduled questionnaire. 
This allowed the study nurses to clearly communicate the 
expectations to the patients participating in the study and 
systematically capture reasons for NR from every patient 
who failed to complete the questionnaire within the 7-day 
response window [60, 61]. Whether patients who were not 
able to complete the questionnaires within the expected time 
frame have a poorer HRQoL will be investigated as part of 
the QoL-MM study.
Conclusions
We evaluated strategies to maximize PRO completion in a 
longitudinal cohort study of patients with MM receiving 
anti-myeloma treatment. Real-time monitoring of NR, elec-
tronic reminders and education of study nurses are effective 
strategies that resulted in a questionnaire completion rate of 
95%. To our knowledge, the QoL-MM study is the first study 
to provide insight into how to ensure high PRO completion 
rates in a cohort of cancer patients receiving chemotherapy. 
We propose our applied strategies as a model for improving 
PRO completion rates in clinical trials, registries and routine 
care management to increase the quality and value of PRO 
data in patient-centred care.
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